MedPath

Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer

Completed
Conditions
Resectable Esophageal Cancer
Registration Number
NCT01858805
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Brief Summary

Despite the availability of several preoperative diagnostic techniques, accurate pretreatment staging of esophageal cancer (EC) remains challenging. Therefore, The investigators evaluated the prognostic significance of circulating tumor cells (CTCs) in patients with EC.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
123
Inclusion Criteria
  • > 18 years
  • resectable esophageal cancer
Exclusion Criteria
  • < 18 years
  • esophageal cancer with preoperative distant metastases

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
overall survival2 years
Secondary Outcome Measures
NameTimeMethod
recurrence-free survival2 years

Trial Locations

Locations (1)

University Hospital Hamburg-Eppendorf

🇩🇪

Hamburg, Germany

University Hospital Hamburg-Eppendorf
🇩🇪Hamburg, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.